Life Science Licensing Group Advises on Award-Winning Collaboration

Thomson Reuters

June 03, 2015

A collaborative agreement between Avalanche Biotechnologies, Inc. and Regeneron Pharmaceuticals, Inc. has been honored with the 2015 “Breakthrough Award for Biopharmaceutical Licensing Deal of the Year” by the life sciences community and Thomson Reuters at Allicense, a prominent industry event held annually in San Francisco.

Latham & Watkins advised Avalanche, the licensor, in the agreement with Regeneron, the licensee, to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The deal was among five contenders selected by Thomson Reuters analysts, which were then put to a public vote to identify the most influential deals executed in 2014.

The award-winning collaboration is another example of the practical solutions to complex life sciences transactions and partnerships developed by the firm’s Life Sciences Licensing Group, which has deep experience advising on innovative industry initiatives.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.